Ftse Mib
37.677,27
-1,44%
DAX
22.328,77
-1,23%
S&P 500
5.572,07
-0,76%
NASDAQ
17.436,10
-0,18%
Bitcoin
83.026,34
5,80%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Sutro Biopharma Inc (STRO) Sutro Biopharma Inc (STRO) Notizie

Sutro Biopharma Inc

STRO
1,28
-0,07 (-5,19%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 21:57:21
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/3/202522:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202500:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202523:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202523:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:05GLOBESutro Biopharma to Present at the TD Cowen 45th Annual..
27/2/202522:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/1/202522:05GLOBESutro Biopharma to Present at the 43rd Annual J.P. Morgan..
07/1/202515:00GLOBESutro Biopharma and Boehringer Ingelheim BioXcellence™..
10/12/202414:00EDGAR2Form 8-K - Current report
10/12/202414:00GLOBESutro Biopharma Announces Selected Dose for Luvelta and..
03/12/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202401:54EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
13/11/202422:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202422:30EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
13/11/202422:30GLOBESutro Biopharma Reports Third Quarter 2024 Financial Results..
12/11/202415:34EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
04/11/202422:05GLOBESutro Biopharma Demonstrates Meaningful ADC Innovation with..
01/11/202413:00GLOBESutro Biopharma Announces Initiation of the..
10/10/202422:05GLOBESutro Biopharma Highlights Next-Generation ADC Innovation..
20/9/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202422:01GLOBESutro Biopharma Announces Inducement Grant Under Nasdaq..
14/9/202409:00GLOBESutro Biopharma Announces Updated Data from Phase 1b Study..
11/9/202414:00GLOBESutro Biopharma to Host Research Forum Highlighting..
22/8/202414:00GLOBESutro Biopharma Announces Initiation of REFRαME-L1 Phase 2..
13/8/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202422:30EDGAR2Form 8-K - Current report
13/8/202422:30GLOBESutro Biopharma Reports Second Quarter 2024 Financial..
13/8/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202422:38EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/8/202422:30EDGAR2Form 8-K - Current report
10/7/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202422:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/7/202414:00GLOBESutro Biopharma Appoints Dr. Barbara Leyman as Chief..
10/6/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:30EDGAR2Form 8-K - Current report
10/6/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
13/5/202422:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202422:30EDGAR2Form 8-K - Current report
13/5/202422:30GLOBESutro Biopharma Reports First Quarter 2024 Financial..
30/4/202414:00GLOBESutro Biopharma Announces Initiation of Randomized Portion..
02/4/202412:18GLOBESutro Biopharma Announces Pricing of $75 Million..
25/3/202421:30GLOBESutro Biopharma Reports Full Year 2023 Financial Results,..
Apertura: 1,35 Min: 1,26 Max: 1,36
Chiusura: 1,35

La tua Cronologia

NASDAQ
STRO
Sutro Biopharma
BIT
P191V8
BNP Paribas Issuance
BIT
S29337
Societe Generale Effekten
BIT
SL
Sanlorenzo
EU
PEUGD
Societe Fonciere Financi...
LSE
SYNT
Synthomer
BIT
19MW
Marvell Technology
LSE
0E6Y
1&1
BIT
P13ZD7
BNP Paribas Issuance
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci